Once-Daily Low-Dose Cyclosporine A Treatment with Angiotensin Blockade for Long-Term Remission of Nephropathy in Frasier Syndrome
Authors:
Open Access
- 1 January 2019
- journal article
- research article
- Published by Tohoku University Medical Press in The Tohoku Journal of Experimental Medicine
- Vol. 247 (1) , 35-40
Abstract
Cyclosporine A is known to be effective in some genetic podocyte injury. However, the efficacy of cyclosporine A depends on the degree of histopathological findings, and the relationship between long-term use and renal prognosis remains unknown. Frasier syndrome is a rare genetic disorder caused by intronic mutations in WT1, and is characterized by progressive glomerulopathy, a 46,XY disorder of sex development, and an increased risk of gonadoblastoma. We report here a 16-year-old phenotypically female patient with Frasier syndrome. A renal biopsy at the age of seven years showed segmentally effaced podocyte foot processes with no evidence of glomerulosclerosis. Steroid-resistant proteinuria progressed to the nephrotic range at the age of 10 years, which responded to once-daily administration of cyclosporine A with low two-hour post-dose cyclosporine A (C2) levels; she then achieved stable partial remission in combination with renin-angiotensin system (RAS) blockade. At the age of 12 years, examinations for delayed puberty confirmed the diagnosis of Frasier syndrome. The second renal biopsy showed widespread foot process effacement and a minor lesion of segmental glomerulosclerosis without findings suggestive of cyclosporine A nephropathy. She maintained partial remission and normal renal function with the continuation of once-daily low-dose cyclosporine A. The C2 levels required for the remission were between 212 and 520 ng/ml. Cyclosporine A dosages sufficient for maintaining the C2 levels were 1.1-1.2 mg/kg per day. In conclusion, the long-lasting treatment of once-daily low-dose cyclosporine A with RAS inhibition was effective for induction and maintenance of partial remission in Frasier syndrome.Keywords
This publication has 22 references indexed in Scilit:
- Rapid Response to Cyclosporin A and Favorable Renal Outcome in Nongenetic Versus Genetic Steroid–Resistant Nephrotic SyndromeClinical Journal of the American Society of Nephrology, 2016
- Towards an understanding of kidney diseases associated with WT1 mutationsKidney International, 2015
- Clinical and Molecular Characterization of Patients with Heterozygous Mutations in Wilms Tumor Suppressor Gene 1Clinical Journal of the American Society of Nephrology, 2015
- The podocyte's response to stress: the enigma of foot process effacementAmerican Journal of Physiology-Renal Physiology, 2013
- Nephrotoxicity of once-daily cyclosporine A in minimal change nephrotic syndromePediatric Nephrology, 2011
- TRPC6 Enhances Angiotensin II-induced AlbuminuriaJournal of the American Society of Nephrology, 2011
- Successful treatment of steroid-resistant nephrotic syndrome associated with WT1 mutationsPediatric Nephrology, 2010
- Risk Factors for Cyclosporin A Nephrotoxicity in Children with Steroid-Dependant Nephrotic SyndromeClinical Journal of the American Society of Nephrology, 2009
- Clinicopathologic Correlation and Outcome of C1q NephropathyClinical Journal of the American Society of Nephrology, 2008
- The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine ANature Medicine, 2008